Castleark Management’s Amedisys AMED Stock Holding History

Castleark Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-58,500	Closed	-$10.7M	–	338
2020 Q1	$10.7M	Sell	58,500 -1,925	-3%	-$342K	0.64%	43
2019 Q4	$10.1M	Buy	+60,425	New	+$8.99M	0.4%	72
2019 Q2	–	Sell	-76,231	Closed	-$9.4M	–	351
2019 Q1	$9.4M	Sell	76,231 -1,424	-2%	-$179K	0.35%	93
2018 Q4	$9.09M	Sell	77,655 -60,445	-44%	-$7.12M	0.39%	76
2018 Q3	$17.3M	Buy	+138,100	New	+$15.3M	0.5%	60
2017 Q3	–	Sell	-58,500	Closed	-$3.67M	–	388
2017 Q2	$3.67M	Buy	+58,500	New	+$3.41M	0.12%	209
2016 Q4	–	Sell	-114,510	Closed	-$5.43M	–	373
2016 Q3	$5.43M	Sell	114,510 -44,015	-28%	-$2.2M	0.16%	169
2016 Q2	$8M	Sell	158,525 -25,840	-14%	-$1.3M	0.26%	116
2016 Q1	$8.91M	Sell	184,365 -4,970	-3%	-$192K	0.28%	93
2015 Q4	$7.45M	Buy	189,335 +200	+0.1%	+$8K	0.22%	116
2015 Q3	$7.18M	Buy	+189,135	New	+$7.98M	0.23%	116

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Castleark Management's AMED Position: Q2 2020 in Review

Castleark Management sold out of Amedisys (AMED) in Q2 2020, closing a stake of 58,500 shares — an estimated $10.7M sold.

Castleark Management first reported a position in AMED in Q3 2015 and held it in 11 quarters. The position peaked at $17.3M in Q3 2018. 354 funds tracked by Wall St. Rank hold AMED as of Q2 2020.

Castleark Management reported no remaining Amedisys position as of Q2 2020 after selling out during the quarter.
Castleark Management sold 58,500 Amedisys shares in Q2 2020, an estimated $10.7M.
Castleark Management first reported a position in Amedisys in Q3 2015 and held it in 11 quarters.
Castleark Management's Amedisys position peaked at $17.3M in Q3 2018.
354 funds tracked by Wall St. Rank held Amedisys as of Q2 2020.

Based on Castleark Management's 13F filing for Q2 2020, filed 14 Aug 2020.